Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
PR Newswire
NEW YORK, July 30, 2024
NEW YORK, July 30, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Marinus investors who were adversely affected by alleged securities fraud between March 17, 2021 and May 7, 2024. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=92696&wire=4
MRNS investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE); (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.
WHAT'S NEXT? If you suffered a loss in Marinus during the relevant time frame, you have until August 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-marinus-pharmaceuticals-incmrns-urged-to-join-class-action--contact-levi--korsinsky-to-learn-more-302208854.html
SOURCE Levi & Korsinsky, LLP
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued